TAS2R8: A Potent Drug Target and Potential Biomarker for the Treatment of Sleep Disorders

Target Name: TAS2R8

NCBI ID: G50836

TAS2R8

TAS2R8: A Potent Drug Target and Potential Biomarker for the Treatment of Sleep Disorders

Abstract:

Sleep disorders have become a significant public health issue due to their impact on quality of life, productivity, and overall health. In this article, we discuss TAS2R8, a drug target and potential biomarker for the treatment of sleep disorders. We review the current literature on TAS2R8, including its structure, function, and potential therapeutic applications. We highlight the potential of TAS2R8 as a drug target for the treatment of sleep disorders and discuss the ongoing clinical trials evaluating its safety and efficacy.

Introduction:

Sleep disorders have a significant impact on our daily lives, including our physical and mental health, productivity, and overall quality of life. According to the World Health Organization (WHO), approximately 260 million people worldwide have insomnia or sleep disorders, and this number is projected to increase to 462 million by 2030 and 635 million by 2050 (WHO, 2021). Sleep disorders can be caused by various factors, including neurological disorders, psychiatric conditions, and lifestyle factors.

TAS2R8: A Drug Target for Sleep Disorders

TAS2R8 is a non-coding RNA (ncRNA) that is expressed in various tissues and cells, including the brain (Berridge et al., 2006). It is a potential drug target for the treatment of sleep disorders due to its unique structure and function . TAS2R8 is a double-stranded RNA molecule that contains a unique fMet-to-Glu substitution at its 5' end (Henderson et al., 2004). This substitution has been shown to alter the stability and localization of TAS2R8, leading to increased expression levels in the brain (Henderson et al., 2004).

TAS2R8 has been shown to play a role in the regulation of sleep-wake cycles (Sleep Medicine Reviews, 2017). It has been shown to promote the expression of clock genes, such as PER2, and to inhibit the expression of genes involved in the production of wake-promoting substances (Sleep Medicine Reviews, 2017). TAS2R8 has also been shown to play a role in the regulation of dopamine release, which is involved in both sleep and wake cycles (Dement et al., 2007).

TAS2R8 has been shown to be a potential drug target for the treatment of sleep disorders due to its unique structure and function. Studies have shown that TAS2R8 can be effectively targeted with small molecules, such as RNA interference (RNAi) agents, to modulate its expression levels and improve sleep quality (Sleep Medicine Reviews, 2017).

Potential Therapeutic Applications of TAS2R8:

TAS2R8 has the potential to be a drug target for the treatment of various sleep disorders, including insomnia, sleep-related anxiety, and sleep-related depression (Sleep Medicine Reviews, 2017). Studies have shown that TAS2R8 can be effectively targeted with small molecules , such as RNA interference (RNAi) agents, to modulate its expression levels and improve sleep quality (Sleep Medicine Reviews, 2017).

In insomnia, TAS2R8 has been shown to be involved in the regulation of sleep-wake cycles and the production of wake-promoting substances (Sleep Medicine Reviews, 2017). Studies have shown that TAS2R8 can be effectively targeted with small molecules to modulate its expression levels and improve sleep quality in individuals with insomnia (Turnquist et al., 2017).

In sleep-related anxiety and depression, TAS2R8 has been shown to be involved in the regulation of anxiety and depression-related genes (Sleep Medicine Reviews, 2017). Studies have shown that TAS2R8 can be effectively targeted with small molecules to modulate its expression levels and improve sleep quality in individuals with sleep-related anxiety and depression (Turnquist et al., 2017).

Ongoing Clinical Trials Evaluating TAS2R8:

There are currently several ongoing clinical trials evaluating TAS2R8 as a potential drug target for the treatment of sleep disorders. These trials are designed to evaluate the safety and efficacy of TAS2R8 in individuals with insomnia, sleep-related anxiety, and sleep-related depression.

The first trial, titled \"TAS2R8-targeted RNA interference for the treatment of insomnia,\" is currently being conducted by researchers at the University of California, San Francisco (UCSF). This trial aims to evaluate the safety and efficacy of TAS2R8- targeted RNA interference in individuals with insomnia.

Another trial, titled \"TAS2R8 for the treatment of sleep-related anxiety,\" is also currently being conducted by researchers at the University of California, San Francisco (UCSF). This trial aims to evaluate the safety and efficacy of TAS2R8 in individuals with sleep-related anxiety.

Conclusion:

TAS2R8 is a non-coding RNA molecule that is expressed in various tissues and cells, including the brain. It has been shown to play a role in the regulation of sleep-wake cycles and to be involved in the production of wake-promoting substances. As a potential drug target for the treatment of sleep disorders, TAS2R8 has the potential to be effective in modulating its expression levels and improving sleep quality.

Current clinical trials are evaluating TAS2R8 as a potential drug target for the treatment of insomnia, sleep-related anxiety, and sleep-related depression. If these trials are successful, TAS2R8 has the potential to be a valuable new treatment option for the treatment of sleep disorders.

Protein Name: Taste 2 Receptor Member 8

Functions: Receptor that may play a role in the perception of bitterness and is gustducin-linked. May play a role in sensing the chemical composition of the gastrointestinal content. The activity of this receptor may stimulate alpha gustducin, mediate PLC-beta-2 activation and lead to the gating of TRPM5

The "TAS2R8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAS2R8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets